Cargando…
Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours
BACKGROUND: Tremelimumab, a fully human cytotoxic T-lymphocyte antigen 4 monoclonal antibody, and PF-3512676, a Toll-like receptor-9 agonist, are targeted immune modulators that elicit durable single-agent antitumour activity in advanced cancer. METHODS: To determine the maximum tolerated dose (MTD)...
Autores principales: | Millward, M, Underhill, C, Lobb, S, McBurnie, J, Meech, S J, Gomez-Navarro, J, Marshall, M A, Huang, B, Mather, C B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670507/ https://www.ncbi.nlm.nih.gov/pubmed/23652314 http://dx.doi.org/10.1038/bjc.2013.227 |
Ejemplares similares
-
Radiosensitization by CpG ODN7909 in an epidermoid laryngeal
carcinoma Hep-2 cell line
por: Wang, Shu, et al.
Publicado: (2017) -
CpG oligodeoxyribonucleotide 7909 enhances radiosensitivity via downregulating Oct-4 expression in radioresistant lung cancer cells
por: Xing, Na, et al.
Publicado: (2015) -
Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909
por: Kuball, Jürgen, et al.
Publicado: (2010) -
Impact of CHK2-small interfering RNA on CpG ODN7909-enhanced radiosensitivity in lung cancer A549 cells
por: Chen, Wei, et al.
Publicado: (2012) -
Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909
por: Duncan, Christopher J. A., et al.
Publicado: (2011)